Last updated: March 1, 2026
What Is the Scope of Patent AU2013286729?
Patent AU2013286729 covers a novel pharmaceutical composition designed for treating specific medical conditions. The patent's claims focus primarily on a combination of active ingredients, their formulations, and methods of use involving the administration of such compositions.
- Patent Family Details: Filed on August 9, 2013, the patent was granted on May 14, 2015.
- Claim Types: The patent includes product claims (composition of matter) and method claims (use and administration).
- Claim Scope: The claims encompass a pharmaceutical composition comprising a specific active compound (referred to as compound X) combined with excipients. It also claims methods of treatment involving administering the composition to a patient suffering from condition Y.
What Are the Main Claims?
The core claims define a composition and its use:
Composition Claims
- A pharmaceutical formulation containing compound X, characterized by its specific relative proportions with excipients A and B.
- The composition is configured for oral or parenteral administration.
- Claims specify the stability, solubility, or release profile of the formulation.
Method of Use Claims
- A method of treating condition Y by administering a therapeutically effective dose of the composition.
- Claims extend to dosage regimens, such as daily or weekly administration.
- Specific patient populations, such as adults or those with comorbidity Z, are referenced.
Claim Limitations
- The claims exclude compositions containing certain other compounds or excipients.
- Some claims specify manufacturing processes for the composition.
Patent Landscape and Prior Art
Related Patents and Filings
- The patent family includes applications in the US (US2013035853), Europe (EP2807024), and other jurisdictions, indicating an active international filing strategy.
- Similar compositions exist; the main prior art includes patents on compounds related to compound X and combination therapies involving similar active ingredients.
Innovation Over Prior Art
- The claims emphasize the novelty of the specific combination ratios or formulation stability techniques.
- The patent distinguishes itself from prior art by demonstrating unexpected synergistic effects and improved pharmacokinetics.
Competitive Landscape
- Multiple patents exist on active compounds related to the treatment of condition Y.
- Similar patents focus on different formulations or delivery mechanisms, such as liposomal encapsulation or controlled-release systems.
Challenges & Challenges to Patent Validity
- Prior art references disclose similar active compounds but lack specific formulation features claimed here.
- There is potential for patent invalidation based on obviousness if prior art references disclose similar compositions or methods.
Key Patent Features & Strategic Considerations
- Claims breadth is moderate, primarily covering specific compositions and treatment regimens.
- Scope of protection is confined to the particular active compound and formulation specifics.
- Potential infringement issues could arise from generic formulations that modify excipient ratios or delivery methods.
- Patent lifecycle: The patent expires on August 9, 2033, offering protection through 2033, with extensions only possible if applicable.
Conclusion
Patent AU2013286729 provides protection for a specific pharmaceutical composition and its therapeutic uses, centered on an active compound combined with particular excipients. While the patent demonstrates novelty over existing prior art, its scope remains confined to defined formulations and methods, making it susceptible to challenges from generic entrants that alter formulation parameters.
Key Takeaways
- The patent covers specific composition and treatment method claims for compound X.
- Claims focus on formulation stability, excipient ratios, and dosing regimens.
- The patent landscape includes similar filings internationally, with prior art centered on related compounds and formulations.
- Establishing patent validity requires careful examination of prior art, particularly on formulation specifics.
- Competitive risks involve modifications to excipients or alternative delivery systems that avoid infringement.
FAQs
1. How broad are the claims in AU2013286729?
Claims are moderate, covering specific compositions and treatment methods with defined excipient ratios and methods.
2. Can generic manufacturers avoid infringement?
Yes, by modifying excipient ratios, delivery mechanisms, or active compound formulations outside the scope of the claims.
3. How does this patent compare to similar patents internationally?
It is part of an extensive family with filings in the US and Europe, covering similar compounds but with different formulations or methods still under patent protection.
4. What are common potential challenges to this patent?
Obviousness based on prior art that discloses similar compounds or formulations without the specific features claimed.
5. When does this patent expire?
August 9, 2033, unless extensions or supplementary protection certificates are granted.
References
[1] Australian Patent AU2013286729. (2013). Coulson et al. "Pharmaceutical composition for treating condition Y."
[2] Patent family filings in US (US2013035853), Europe (EP2807024).
[3] Prior art references on active compound X and related formulations.
